Second-line treatment of diffuse large B‐cell lymphoma: Evolution of options

Fabbri, N.; Mussetti, A.; Sureda, A.

doi:10.1053/j.seminhematol.2023.12.001

Cited by 3 publications

(1 citation statement)

References 97 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Применение иммунохимиотерапевтических режимов с включением анти-CD20-антитела ритуксимаба у больных с впервые диагностированной ДВККЛ позволило достигнуть ремиссии в 60-70 % наблюдений. Однако в 30-40 % случаев возникает рецидив, рефрактерный к последующему лечению почти в половине наблюдений [29,30]. Для пациентов, не являющихся кандидатами для проведения высокодозной химиотерапии (ВДХТ) с аутологичной трансплантацией гемопоэтических стволовых клеток (аутоТГСК), в такой ситуации методы лечения ограничены.…”

Section: Discussionunclassified

Polatuzumab vedotin in diffuse large B-cell lymphoma therapy: Literature review and experience of the Oncohematology Division of the Lapino Clinical Hospital

Ryabukhina,

Zeynalova,

Timofeeva

et al. 2024

jour

View full text Add to dashboard Cite

Study of molecular and genetic features of diffuse large B-cell lymphoma (DLBCL) suggests differential approach to treatment of this aggressive B-cell disorder characterized by short remission after each subsequent therapy line. Therefore, more effective regimens should be used at earlier stages. Identification of biological markers and their integration into prognostic scales can help to personalize therapy, especially in patients with high risk of quick progression and increase survival.Our own experience of using immunoconjugate polatuzumab vedotin in therapy of patients with DLBCL. The use of Pola-BR combination in a patient with refractory non-GCB DLBCL allowed to achieve full remission alongside satisfactory tolerability and absence of significant adverse events. An evaluation of the Pola-R-CHP regimen in treatment of a patient with newly diagnosed generalized GCB DLBCL is presented.

show abstract

Section: Discussionunclassified

Polatuzumab vedotin in diffuse large B-cell lymphoma therapy: Literature review and experience of the Oncohematology Division of the Lapino Clinical Hospital

Ryabukhina,

Zeynalova,

Timofeeva

et al. 2024

jour

View full text Add to dashboard Cite

show abstract

Introduction to series: Diffuse large B-cell lymphoma

Smith,

Pasqualucci

2023

Seminars in Hematology

View full text Add to dashboard Cite

Time‐dependent cost comparison and health economic impact analysis of second‐line interventions for transplant‐ineligible patients with relapsed or refractory diffuse large B cell lymphoma

Kurte,

Siefen,

Jakobs

et al. 2024

European J of Haematology

View full text Add to dashboard Cite

ObjectivesNovel interventions (axicabtagene ciloleucel [axi‐cel], lisocabtagene maraleucel [liso‐cel], tafasitamab‐lenalidomide [Tafa‐L], polatuzumab‐rituximab‐bendamustine [pola‐BR]) improve clinical outcomes in second‐line (2 L) treatment of transplant‐ineligible patients with early relapse or refractory (R/R) diffuse large B cell lymphoma (DLBCL). The costs vary depending on the respective treatment regimen and the treatment duration, difficult comparability in reimbursement decisions. The objective was to analyze the health economic impacts of novel 2 L interventions and conventional immunochemotherapies (bendamustine‐rituximab [BR], rituximab‐gemcitabine‐oxaliplatin [R‐GemOx]) from a German healthcare payer's perspective as a function of treatment duration.MethodsAn economic model was developed to compare treatment costs of 2 L interventions depending on the treatment duration. Treatment duration was measured by progression‐free survival (PFS), identified based on a systematic review. Total and average costs were calculated over 5 years to evaluate incremental costs at median PFS for each intervention.ResultsAverage costs per month at median PFS ranged from €2846 (95% CI: 5067‐1641) to €40 535 (95% CI: 91180‐N/A) for BR and liso‐cel, respectively. Incremental costs at the lowest median PFS (R‐GemOx: 5.3 months) revealed −€664, €5560, €11 817, €53 145, and €67 745 for BR, Tafa‐L, pola‐BR, axi‐cel, and liso‐cel as compared to R‐GemOx, respectively.ConclusionsAnalyses uncovered a variation of incremental costs of 2 L transplant‐ineligible DLBCL interventions as a function of time leading to amortization of high‐priced interventions.

show abstract

Second-line treatment of diffuse large B‐cell lymphoma: Evolution of options

Cited by 3 publications

References 97 publications

Polatuzumab vedotin in diffuse large B-cell lymphoma therapy: Literature review and experience of the Oncohematology Division of the Lapino Clinical Hospital

Polatuzumab vedotin in diffuse large B-cell lymphoma therapy: Literature review and experience of the Oncohematology Division of the Lapino Clinical Hospital

Introduction to series: Diffuse large B-cell lymphoma

Time‐dependent cost comparison and health economic impact analysis of second‐line interventions for transplant‐ineligible patients with relapsed or refractory diffuse large B cell lymphoma

Contact Info

Product

Resources

About